Nuvelution Pharma

601 Gateway Boulevard
Suite 1270
South San Francisco
California
94080
United States

Tel: 650-866-8065??

About Nuvelution Pharma

Nuvelution leverages its extensive knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources with the goal of making this model an essential tool for pharma and biotech companies to bring products to the market.
YEAR FOUNDED:
June 2015
LEADERSHIP:
President & CEO: Sanford (Sandy) Zweifach
CBO: James Cornwall, PhD
CFO: Joe Poirier
Chief Physician Scientist: Barry Gertz, MD, PhD
VP, Clinical Operations: Heather Smith

8 articles about Nuvelution Pharma

Nuvelution Pharma Appoints Ronald Martell as President and CEO

12/4/2019

Nuvelution Pharma, Inc., announced that Ronald Martell, has been appointed as President and Chief Executive Officer. He will also serve on the Company’s Board of Directors.
BioSpace Movers and Shakers: Feb. 1

2/1/2019

As January ends, biotech and pharma companies tap new leaders to help drive strategic visions. New hires at Histogen, Indalo, Novartis Oncology, Calico, and more.
Nuvelution Pharma Appoints Milena Kanova-Petrova, M.D., as Senior Vice President of Operations

1/29/2019

Nuvelution Pharma, Inc. announced the appointment of Milena Kanova-Petrova, M.D., as Senior Vice President of Operations effective immediately.
Nuvelution Pharma Appoints PwC Veteran Mary Dolson to its Board of Directors

1/7/2019

Nuvelution Pharma, Inc., announced the appointment of Mary Dolson, a former partner of PricewaterhouseCoopers (“PwC”), to its Board of Directors
BioSpace Movers and Shakers Oct. 29

10/29/2018

Biopharma companies shore up leadership roles with new hires and appointments, at Axcella Health, Twist Bioscience, and more.
Nuvelution Pharma Appoints Kirk Ways, M.D., Ph.D., as Chief Medical Officer

10/25/2018

Dr. Ways is a seasoned industry expert with over 30 years of experience in medical research and will support the Company’s objective in advancing late-stage clinical assets toward FDA approval.
Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO® (deutetrabenazine) for the Treatment of Tourette Syndrome in Pediatric Patients

2/28/2018

AUSTEDO® was approved by the U.S. FDA for the treatment of chorea associated with Huntington’s disease in April 2017 and for tardive dyskinesia in adults in August 2017.
Teva And Nuvelution Pharma Partner To Accelerate Development Of AUSTEDO (Deutetrabenazine) Tablets For Use In Tourette Syndrome In The United States

9/19/2017